Previous 10 | Next 10 |
home / stock / nicxf / nicxf news
CONSOLIDATED STATEMENTS OF PROFIT OR LOSS (1) Includes in 2022 an additional non-cash adjustment on NCX 4251 fair value, decreasing by €(10.9) million due to the decision to seek a partner to pursue the development of NCX 4251 in the U.S. Includes in 2021 two non...
Attachment EN_Presentations at scientific conferences PR_20230303_F1
Attachment EN_H1 2023 conferences_PR_20230124_F
1 Net revenue consists of revenue from collaborations less royalty payments which corresponds to Net profit in the consolidated statements of profit or loss 2 Bloomberg data comparing the period of the weeks ending October 7, 2022 to December 30, 2022 with the period of the weeks ending October...
Press Release Nicox Announces Proposed Move to Euronext Growth Paris Intention to transfer listing from the Euronext Paris regulated market to Euronext Growth Paris Ordinary shareholder meeting convened on February 14, 2023 January 9, 2023...
Nicox (OTCPK:NICXF) has appointed Doug Hubatsch to lead all of the Company’s non-clinical and clinical development activities and will be based in Nicox’s US subsidiary Nicox Ophthalmics Inc., in Durham, North Carolina.. As Chief Scientific Officer, Doug Huba...
Bausch Health Companies (BHC) and Nicox (NICXF) announce that VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency. VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle gl...
Nicox (NICXF): Q3 Revenue of €0.8M (+60.0% Y/Y).As of September 30, 2020, the company had cash and cash equivalents of €42.2M vs. €28M at December 31, 2019.For the quarter, VYZULTA U.S. prescriptions increased by 45% Y/Y and ZERVIATET U.S. pr...
Tarsus Pharmaceuticals has filed to raise $80 million from the sale of its common stock in a U.S. IPO. The firm is in Phase 3 trials for its treatment for Demodex blepharitis. With strong efficacy results and a reasonable IPO price, the IPO is worth considering for life science in...
Nicox SA ( OTCPK:NICXF ) has initiated the first Phase 3 clinical trial, named Mont Blanc, evaluating NCX 470 for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, by enrolling the first 12 patients. More news on: Nicox S.A., Healthca...
News, Short Squeeze, Breakout and More Instantly...
Nicox SA Company Name:
NICXF Stock Symbol:
OTCMKTS Market:
Attachment EN_DenaliLastUSPatient_PR_FINAL
Attachment EN_Nicox Conferences 2024_FINAL
1 Net revenue consists of revenue from collaborations less royalty payments 2 Intra-ocular pressure Attachment EN_Q22024Results_PR_FINAL